Long-term cardiac safety and outcomes of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).

Authors

C. T. Dang

Memorial Sloan-Kettering Cancer Center, New York, NY

C. T. Dang , P. G. Morris , S. Patil , C. Chen , A. Abbruzzi , R. Lehman , R. Steingart , L. Norton , C. Hudis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 Breast Cancer Symposium

bookmark_border

Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).

First Author: Neil M. Iyengar

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).

First Author: Patrick Glyn Morris

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer.

First Author: Rui Wang

insert_chart_outlined

Poster

2014 ASCO Annual Meeting

bookmark_border

Long-term cardiac safety analysis of NCCTG (Alliance) N9831 adjuvant trastuzumab (H) trial.

First Author: Pooja Prem Advani